{"id":960,"date":"2008-02-01T12:01:00","date_gmt":"2008-02-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/neuere-orale-antidiabetika-kein-vorteil-gegenueber-metformin-und-sulfonylharnstoff-derivaten-der-zweiten-generation"},"modified":"2008-02-01T12:01:00","modified_gmt":"2008-02-01T11:01:00","slug":"neuere-orale-antidiabetika-kein-vorteil-gegenueber-metformin-und-sulfonylharnstoff-derivaten-der-zweiten-generation","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/neuere-orale-antidiabetika-kein-vorteil-gegenueber-metformin-und-sulfonylharnstoff-derivaten-der-zweiten-generation","title":{"rendered":"Neuere orale Antidiabetika: Kein Vorteil gegen\u00fcber Metformin und Sulfonylharnstoff-Derivaten der zweiten Generation"},"content":{"rendered":"<p>W\u00e4hrend die Debatte \u00fcber Nutzen und Risiken von Thiazolidindionen (Pioglitazon = Actos\u00ae; Rosiglitazon = Avandia\u00ae) \u00fcber die wir mehrfach berichtet haben (1-5), unvermindert weiter geht (6-9), erschien k\u00fcrzlich in den Ann. Intern. Med. ein umfangreicher systematischer vergleichender Review \u00fcber die Wirksamkeit und Sicherheit aller verf\u00fcgbaren oralen Antidiabetika (OAD) aus der Feder von S. Bolen von [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>W\u00e4hrend die Debatte \u00fcber Nutzen und Risiken von Thiazolidindionen (Pioglitazon = Actos\u00ae; Rosiglitazon = Avandia\u00ae) \u00fcber die wir mehrfach berichtet haben (1-5), unvermindert weiter geht (6-9), erschien k\u00fcrzlich in den Ann. Intern. Med. ein umfangreicher systematischer vergleichender Review \u00fcber die Wirksamkeit und Sicherheit aller verf\u00fcgbaren oralen Antidiabetika (OAD) aus der Feder von S. Bolen von [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1146,155,2460,1730,1876,157,1866,2459],"class_list":["post-960","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acarbose","tag-diabetes-mellitus-typ-2","tag-meglitinide","tag-metformin","tag-nateglinid","tag-orale-antidiabetika","tag-repaglinid","tag-thiazolidindione"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=960"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/960\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}